Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (371-380 of 386) with videos related to

Pageof 39
Sort By:
Pharmacology & Therapeutics|August 25, 2010
The development of MDA-7/IL-24 as a cancer therapeuticPaul Dent, Adly Yacoub, Hossein A Hamed, et al.
Blood Advances|August 31, 2021
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanismsLiang Zhou, Yu Zhang, Mark B Meads, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Neuroimage|June 20, 2021
Meaningful associations in the adolescent brain cognitive development studyAnthony Steven Dick, Daniel A Lopez, Ashley L Watts, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 28, 2014
Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseasesJenny H Xie, Aaron P Yamniuk, Virna Borowski, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell LymphomaVictor Yazbeck, Danielle Shafer, Edward B Perkins, et al.
Developmental Cognitive Neuroscience|October 21, 2017
The conception of the ABCD study: From substance use to a broad NIH collaborationNora D Volkow, George F Koob, Robert T Croyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
Pageof 39

Showing results (371-380 of 386) with videos related to

Sort By:
Pageof 39
Pharmacology & Therapeutics|August 25, 2010
The development of MDA-7/IL-24 as a cancer therapeuticPaul Dent, Adly Yacoub, Hossein A Hamed, et al.
Blood Advances|August 31, 2021
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanismsLiang Zhou, Yu Zhang, Mark B Meads, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Neuroimage|June 20, 2021
Meaningful associations in the adolescent brain cognitive development studyAnthony Steven Dick, Daniel A Lopez, Ashley L Watts, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 28, 2014
Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseasesJenny H Xie, Aaron P Yamniuk, Virna Borowski, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell LymphomaVictor Yazbeck, Danielle Shafer, Edward B Perkins, et al.
Developmental Cognitive Neuroscience|October 21, 2017
The conception of the ABCD study: From substance use to a broad NIH collaborationNora D Volkow, George F Koob, Robert T Croyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
Pageof 39